Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor

Immunity

Volumn 44, Issue 4, 2016, Pages 939-950

  Kong, Leopold ^a   Ju, Bin ^b   Chen, Yajing ^a   He, Linling ^a   Ren, Li ^b   Liu, Jiandong ^b   Hong, Kunxue ^b   Su, Bin ^c   Wang, Zheng ^b   Ozorowski, Gabriel ^a   Ji, Xiaolin ^b   Hua, Yuanzi ^a   Chen, Yanli ^b   Deller, Marc C ^a   Hao, Yanling ^b   Feng, Yi ^b   Garces, Fernando ^a   Wilson, Richard ^a   Dai, Kaifan ^a   O'Dell, Sijy ^d   McKee, Krisha ^d   Mascola, John R ^d   Ward, Andrew B ^a   Wyatt, Richard T ^a   Li, Yuxing ^e   Wilson, Ian A ^a   Zhu, Jiang ^a   Shao, Yiming ^b,f,g   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^g NANKAI UNIVERSITY   (China)

Author keywords

Antibody maturation; B cell development; Broadly neutralizing antibodies; CD4 binding site; Glycan shield; Gp120; HIV infection; Rational vaccine design; Virus host co evolution; VRC01 class

Indexed keywords

GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DRVIA7; UNCLASSIFIED DRUG; VRC01 ANTIBODY; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VRC01 MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ARTICLE; B LYMPHOCYTE; CELL SELECTION; HEAVY CHAIN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIGHT CHAIN; LYMPHOCYTE FUNCTION; LYMPHOCYTE STRUCTURE; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES, ANTIBODY; CD4-POSITIVE T-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 84962201516     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.03.006     Document Type: Article

References (41)

1. Burton D.R., Mascola J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015, 16:571-576.
2. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., Hessell A.J., Pancera M., Tang M., Xu L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
3. de Taeye S.W., Ozorowski G., Torrents de la Peña A., Guttman M., Julien J.-P., van den Kerkhof T.L.G.M., Burger J.A., Pritchard L.K., Pugach P., Yasmeen A., et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 2015, 163:1702-1715.
4. deCamp A., Hraber P., Bailer R.T., Seaman M.S., Ochsenbauer C., Kappes J., Gottardo R., Edlefsen P., Self S., Tang H., et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2014, 88:2489-2507.
5. Derking R., Ozorowski G., Sliepen K., Yasmeen A., Cupo A., Torres J.L., Julien J.-P., Lee J.H., van Montfort T., de Taeye S.W., et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 2015, 11:e1004767.
6. Diskin R., Scheid J.F., Marcovecchio P.M., West A.P., Klein F., Gao H., Gnanapragasam P.N.P., Abadir A., Seaman M.S., Nussenzweig M.C., Bjorkman P.J. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334:1289-1293.
7. Freund N.T., Horwitz J.A., Nogueira L., Sievers S.A., Scharf L., Scheid J.F., Gazumyan A., Liu C., Velinzon K., Goldenthal A., et al. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog. 2015, 11:e1005238.
8. Gray E.S., Madiga M.C., Hermanus T., Moore P.L., Wibmer C.K., Tumba N.L., Werner L., Mlisana K., Sibeko S., Williamson C., et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011, 85:4828-4840. CAPRISA002 Study Team.
9. He L., Sok D., Azadnia P., Hsueh J., Landais E., Simek M., Koff W.C., Poignard P., Burton D.R., Zhu J. Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. Sci. Rep. 2014, 4:6778.
10. Hu X., Hong K., Zhao C., Zheng Y., Ma L., Ruan Y., Gao H., Greene K., Sarzotti-Kelsoe M., Montefiori D.C., Shao Y. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. J. Gen. Virol. 2012, 93:2267-2278.
11. Jardine J., Julien J.-P., Menis S., Ota T., Kalyuzhniy O., McGuire A., Sok D., Huang P.-S., MacPherson S., Jones M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
12. Jardine J.G., Ota T., Sok D., Pauthner M., Kulp D.W., Kalyuzhniy O., Skog P.D., Thinnes T.C., Bhullar D., Briney B., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015, 349:156-161.
13. Julien J.-P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.-J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
14. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., Nussenzweig M.C. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
15. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.-P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.-J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
16. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
17. Kwong P.D., Mascola J.R., Nabel G.J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 2013, 13:693-701.
18. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 2007, 13:1032-1034.
19. Li Z., He X., Wang Z., Xing H., Li F., Yang Y., Wang Q., Takebe Y., Shao Y. Tracing the origin and history of HIV-1 subtype B' epidemic by near full-length genome analyses. AIDS 2012, 26:877-884.
20. Lyumkis D., Julien J.-P., de Val N., Cupo A., Potter C.S., Klasse P.-J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
21. Ma Y., Li Z., Zhao S. HIV infected people were first identified in intravenous drug users in China. Chin. J. Epidemiol. 1990, 11:184-185.
22. Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011, 7:e1001251.
23. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.-Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
24. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.A., Farmer P., Hunter E., Allen S., et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970.
25. Scharf L., Scheid J.F., Lee J.H., West A.P., Chen C., Gao H., Gnanapragasam P.N.P., Mares R., Seaman M.S., Ward A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014, 7:785-795.
26. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y.K., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
27. Tomaras G.D., Binley J.M., Gray E.S., Crooks E.T., Osawa K., Moore P.L., Tumba N., Tong T., Shen X., Yates N.L., et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 2011, 85:11502-11519.
28. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
29. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6:e1001028.
30. Wang W., Zirkle B., Nie J., Ma J., Gao K., Chen X.S., Huang W., Kong W., Wang Y. N463 glycosylation site on V5 loop of a mutant gp120 regulates the sensitivity of HIV-1 to neutralizing monoclonal antibodies VRC01/03. J. Acquir. Immune Defic. Syndr. 2015, 69:270-277.
31. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
32. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602. NISC Comparative Sequencing Program.
33. Wu X., Wang C., O'Dell S., Li Y., Keele B.F., Yang Z., Imamichi H., Doria-Rose N., Hoxie J.A., Connors M., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 2012, 86:5844-5856.
34. Wu X., Zhang Z., Schramm C.A., Joyce M.G., Kwon Y.D., Zhou T., Sheng Z., Zhang B., O'Dell S., McKee K., et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 2015, 161:470-485. NISC Comparative Sequencing Program.
35. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
36. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 2002, 76:4634-4642.
37. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.-H., Yang X., Zhang M.-Y., Zwick M.B., Arthos J., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
38. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
39. Zhou T., Zhu J., Wu X., Moquin S., Zhang B., Acharya P., Georgiev I.S., Altae-Tran H.R., Chuang G.-Y., Joyce M.G., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013, 39:245-258. NISC Comparative Sequencing Program.
40. Zhou T., Lynch R.M., Chen L., Acharya P., Wu X., Doria-Rose N.A., Joyce M.G., Lingwood D., Soto C., Bailer R.T., et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015, 161:1280-1292. NISC Comparative Sequencing Program.
41. Zhu J., Wu X., Zhang B., McKee K., O'Dell S., Soto C., Zhou T., Casazza J.P., Mullikin J.C., Kwong P.D., et al. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc. Natl. Acad. Sci. USA 2013, 110:E4088-E4097. NISC Comparative Sequencing Program.